Table 1.
Baseline characteristics of patients
| Characteristic | Patients (n = 40) |
|---|---|
| Age, years, median (range) | 56 (27–76) |
| ECOG PS score, n (%) | |
| 0 | 3 (7.5%) |
| 1 | 37 (92.5%) |
| Number of metastatic sites, median (range) | 2 (0–5) |
| Metastatic sites, n (%) | |
| Lymph nodes | 25 (62.5%) |
| Lung | 9 (22.5%) |
| Liver | 9 (22.5%) |
| Others* | 26 (65.0%) |
| Previous lines of chemotherapy in the advanced setting, median (range) | 2 (1–5) |
| Previous therapy in the advanced setting, n (%) | |
| Taxane | 24 (60.0%) |
| Anthracycline | 32 (80.0%) |
| Platinum | 20 (50.0%) |
| Others# | 34 (85.0%) |
* Including 13 patients with bone metastasis, one with brain metastasis, two with skin or soft tissue metastasis, 16 with chest wall metastasis, and two with adrenal metastasis
# Including 15 patients given capecitabine, 13 given cyclophosphamide, ten given gemcitabine, nine given vinorelbine, one given fluorouracil, one given eribulin, one given utidelone and one given raltitrexed
ECOG PS: Eastern Cooperative Oncology Group performance status